Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors.

Trial Profile

Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Hyaluronidase (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 26 Sep 2017 According to results published in the British Journal of Cancer, the study protocol was amended with a change of starting dose from 50ugkg-1 dose to 0.5ugkg-1 dose twice weekly.Later on the schedule was adjusted to every 21 days.
    • 26 Sep 2017 Results published in the British Journal of Cancer.
    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top